Sanofi CEO: Vaccines business 'continues to deliver'

Sanofi Pasteur

Sanofi continues to lean on its vaccines offerings as other areas struggle. The French pharma’s vaccines unit Sanofi Pasteur “continues to deliver” and posted “good growth” in Q1, CEO Olivier Brandicourt told investors in discussing the results.

Driven by increased sales for polio, pertussis and Hib vaccines in emerging markets and Menactra's performance in the U.S., Sanofi grew vaccine sales 8.2% to €625 million ($719 million) for the quarter. It did this despite battling Pentacel supply constraints in the U.S., where overall vaccine sales were down 17.3%.

During the quarter, Sanofi recorded its first Dengvaxia sales, which rang in at €19 million and came from an immunization campaign just getting underway in the Philippines. On the earnings call, Brandicourt noted that the company recently submitted a "dossier for approval” for the first-in-its-class dengue vaccine to European regulators.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

That vaccine got a boost last month from a WHO committee recommendation that countries where dengue is prevalent incorporate it into a comprehensive strategy to control the virus. With four approvals in hand, Sanofi anticipates further Dengvaxia regulatory blessings and new announcements surrounding immunization strategies. Analysts have said the vaccine could reach $1.4 billion in sales by 2020.

During the quarter, Sanofi decided to call off its vaccines JV with Merck in Europe, a move executives explained will allow the company to “allocate our resources behind our brand where we continue to see strong potential.”

Last year, Sanofi Pasteur grew sales 15% to €4.74 billion. The unit’s performance holds importance at the French pharma, where other revenues such as those from the flagship diabetes franchise have suffered in recent years. Diabetes and cardiovascular sales at Sanofi were down 5.8% in Q1.

- here's the release
- and a transcript of the conference call from Seeking Alpha

Related Articles:
Sanofi, Merck to split up their long-standing vaccines JV in Europe
Sanofi's Dengvaxia gets a boost from WHO recommendation
As corporate restructuring looms, Sanofi's vaccines deliver in 2015

Pictured is a Sanofi Pasteur R&D lab technician, courtesy of CNW Group and Sanofi Pasteur.


Suggested Articles

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.

Merck & Co.'s Fosamax fight has lasted for years—and now, thanks to a U.S. Supreme Court ruling Monday, Merck gets yet another chance to press its…

Mallinckrodt’s Acthar Gel has seen its share of lawsuits, but the company was happy to launch another—this time to defend its Medicaid business.